Captor is now well positioned to go global through its two-pronged approach to TPD discovery and development, advancing both a molecular glue and a bifunctional degrader toward the clinic.

These molecules are designed to self-assemble to form the full bifunctional degrader at the intended location in the body. Their small size greatly facilitates oral bioavailability and the ability ...